卵巣癌、胃癌、および結腸直腸癌の有病率の増加、低侵襲手術に対する高い需要、臨床検査における技術開発、バイオインフォマティクスなどのデータ共有および分析のためのインフラの巨大な開発、およびゲノムバイオマーカーベースの個別化医療に関する意識の高まりなどが、ゲノムバイオマーカー市場の成長を推進する主な要因です。
目次
Contents
1. Executive Summary
2. Global Genomic Biomarkers Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Genomic Biomarkers Market Analysis
10.1. Porter Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Genomic Biomarkers Market
11.1. Market Size & forecast, 2020A-2031F
11.1.1. By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
11.1.2. By Volume (Million Units) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12. Global Genomic Biomarkers Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.1.5. the Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2. By Type: Market Share (2020-2031F)
12.2.1. Oncology, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.2. Cardiovascular diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.3. Neurological diseases, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.4. Renal Disorders, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
12.2.5. Others, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13. By End-user: Market Share (2020-2031F)
13.1. Hospital, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13.2. Diagnostic center, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
13.3. Others, By Value (USD Million) 2020-2031F; Y-o-Y Growth (%) 2021-2031F
14. Company Profile
14.1. Qiagen
14.1.1. Company Overview
14.1.2. Company Total Revenue (Financials)
14.1.3. Market Potential
14.1.4. Global Presence
14.1.5. Key Performance Indicators
14.1.6. SWOT Analysis
14.1.7. Product Launch
14.2. Almac Group
14.3. Cancer Genetics Inc
14.4. Eurofins Scientific
14.5. Thermo Fisher Scientific Inc
14.6. Aepodia SA
14.7. Epigenomics AG
14.8. US Biomarkers Inc.
14.9. Roche Diagnostics
14.10. Other Prominent Players
14.10.1. Consultant Recommendation
14.10.2. The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
